Levores

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levores

What is Levores?

Property Description
Active Ingredient Levofloxacin
Pharmacological Class Fluoroquinolone Antibiotic
Common Use Combating systemic bacterial infections
Primary Forms Tablet, Injectable Solution, Ophthalmic Solution
Origin Synthetic (L-isomer of Ofloxacin)

Levores is a prescription-only systemic antibiotic medication that serves to resolve a broad range of systemic bacterial infections throughout the body. The drug is clinically recognized for its efficacy against infections requiring systemic intervention. Its purpose is defined by its core active ingredient, Levofloxacin, which is a powerful agent against susceptible pathogenic microorganisms. This medicine is classified as a synthetic compound and belongs to the Fluoroquinolone class of antibiotics, a category known for its specific and highly effective mode of action.

What Type of Medicine is Levores (Levofloxacin)?

Levores is classified pharmacologically as a Fluoroquinolone antibiotic, which means it is a fully synthetic agent designed for therapeutic potency. The active ingredient, Levofloxacin, is distinct as it is the purified L-isomer of the older quinolone drug Ofloxacin, providing a focused, more active compound. This formulation is used to address complex bacterial threats, such as in instances requiring systemic intervention for respiratory or skin infections.

Composition and Available Forms of Levores

The composition of Levores is monosemantic, containing the single active ingredient, Levofloxacin, combined with pharmaceutical excipients necessary for stability and delivery. To suit different patient needs and routes of administration, Levores is supplied in several pharmaceutical preparations, including a tablet for oral intake, an oral solution, and an injectable solution designated for intravenous administration. Furthermore, it is available as an ophthalmic solution (eye drops) for targeted topical use. The versatility of these formulations ensures the medicine can be delivered for both systemic and localized uses.

How Does Levofloxacin Work to Fight Infections?

Levofloxacin acts as a bactericidal agent, working by directly killing the bacterial cells responsible for the infection, rather than merely pausing their growth. This broad-spectrum antibiotic achieves its effect by interfering with two essential bacterial enzymes, DNA gyrase and topoisomerase IV. By disabling these vital components, Levofloxacin halts the bacteria's ability to replicate and maintain its genetic material, which ultimately results in the elimination of the pathogen.

Regulatory References

  1. National Library of Medicine Source

What side effects are possible with Levores?

Possible Side Effects and Safety Information

The safety profile of Levores, which contains the active ingredient Levofloxacin, is defined by a range of adverse reactions classified by frequency and system involvement, as documented in official regulatory sources (FDA, EMA).

Common adverse reactions—those observed in at least 1 in 100 patients—often include gastrointestinal disorders such as nausea, diarrhea, vomiting, and abdominal pain, alongside nervous system effects like headache, dizziness, and insomnia.

Serious and Potentially Disabling Adverse Reactions

Regulatory documentation highlights the risk of serious adverse reactions associated with the fluoroquinolone class. These include effects that can be prolonged, disabling, and potentially irreversible.

Key serious adverse reactions include Tendinopathy and Tendon Rupture (most commonly affecting the Achilles tendon), and Peripheral Neuropathy (nerve damage). The official label also notes the risk of severe Hypoglycaemia (low blood sugar), significant Central Nervous System effects (e.g., memory impairment, psychotic reactions), and, less frequently, Aortic Aneurysm and Dissection.

Safety notes specify that tendon issues may occur rapidly (within 48 hours of starting treatment) or be delayed (up to several months after discontinuation).

Population-Specific Safety Notes

The risk profile differs for certain patient groups. Older adults (age 60 and above) and patients taking concomitant corticosteroids are at an increased risk of tendon disorders. Levores is generally contraindicated for use in children and growing adolescents due to the risk of musculoskeletal joint damage, as well as in patients with a history of Epilepsy or tendon problems related to previous quinolone use.

Overdose and Emergency Response

The official regulatory documentation for Levofloxacin (Levores) describes specific manifestations and necessary emergency actions in the event of an acute overdosage. Officially documented clinical signs primarily involve the Central Nervous System (CNS), which may include manifestations such as confusion, dizziness, and convulsions (seizures), alongside gastrointestinal effects like nausea. Additionally, high-dose exposure carries an important risk for the cardiovascular system, specifically the prolongation of the QT interval. This cardiac abnormality is associated with the potential for serious ventricular arrhythmias, including torsade de pointes.

In any situation involving a suspected overdose, regulatory guidance unequivocally mandates that patients must seek emergency medical attention immediately or contact the Poison Help line. This immediate action is required due to the potential severity of the documented CNS and cardiac effects. Management described in official prescribing information is symptomatic and supportive, emphasizing that no specific antidote is known. Procedural steps include emptying the stomach, maintaining appropriate hydration, and ensuring the patient is observed. An important procedural note for healthcare providers is that Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis, a consideration relevant for certain overdose cases.

Therapeutic Uses of Levores

What Levores Treats: Main Uses and Benefits

Levores is a medication that is commonly used to treat serious bacterial infections where the symptoms create noticeable physiological strain and are associated with acute or disruptive episodes. Its primary therapeutic benefit is that it plays a role in managing the infection, which assists in stabilizing the patient during difficult episodes and assists with maintaining functional stability. Its clinical application is primarily for serious bacterial diseases.

It is commonly used to help manage infections across several therapeutic areas: severe lower respiratory tract infections, including Community-Acquired Pneumonia and Nosocomial Pneumonia; complicated urogenital infections, such as Acute Pyelonephritis and Complicated Urinary Tract Infections; and deep-seated tissue infections, like advanced Complicated Skin and Skin Structure Infections (SSSI). Additionally, it is applied in specialized, high-risk contexts, including management or supportive assistance for Inhalational Anthrax and Plague.


Quick Fact: Support for Systemic Discomfort Levores assists with managing symptoms related to systemic imbalance and acute inflammation, supporting patients during episodes of heightened discomfort associated with severe bacterial infection.

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Levores (Levofloxacin)

Official regulatory documents strictly define the patient populations eligible for systemic Levores use.


Contraindicated Populations (Must Not Use)

Classification Population Restriction
Absolute Contraindication History of hypersensitivity to Levofloxacin or any other Fluoroquinolone.
Absolute Contraindication Patients with a history of tendon disorders related to prior fluoroquinolone exposure.
Absolute Contraindication Patients with a known history of myasthenia gravis (due to risk of exacerbation).
Age-Group Exclusion Systemic use is generally contraindicated in children and growing adolescents (typically under 18 years) due to the risk of joint damage.

Condition-Based Restrictions and Conditional Use

Condition/Status Eligibility Status
Renal Impairment Conditional Use: Patients with impaired kidney function (e.g., Creatinine Clearance < 50 mL/min) require a mandatory dosage adjustment as stated in the label.
Pregnancy/Lactation Not Recommended/Contraindicated: Use is generally prohibited or advised against in pregnant and breastfeeding women.
Comorbidities Use with Caution: Restrictions apply to patients with a predisposition to seizures (e.g., epilepsy, CNS disorders) or conditions that prolong the QT interval (e.g., hypokalemia, pre-existing cardiac risk).

Resulting Eligibility Structure

Eligibility is established primarily for Adults (ge 18 years of age). Systemic use in pediatric patients (ge 6 months) is officially reserved only for specific, life-threatening infections, such as Inhalational Anthrax or Plague, when no alternative treatments are available. This framework dictates who is officially allowed to use the medicine according to governmental labeling.

What should I know about interactions with other medicines?

Levores (Levofloxacin) can interact with several other medicines and products, which may affect how it works or increase the risk of serious side effects.

Interactions that Affect Drug Absorption

Oral Levores tablets or solution should not be taken within two hours of products containing multivalent cations. This includes antacids (containing magnesium or aluminum), sucralfate, and supplements containing iron or zinc. These products bind to Levores in the digestive tract, which can significantly decrease the amount of the antibiotic absorbed into the body, potentially reducing its effectiveness.

Interactions that Increase Safety Risks

  • Corticosteroids (e.g., Prednisone): Co-administration increases the risk of tendinitis and tendon rupture. This risk is particularly heightened in patients over 60 years old and those with organ transplants.
  • Warfarin: Levores may enhance the anticoagulant effect of warfarin, leading to an increased risk of bleeding. Close and frequent monitoring of coagulation tests (such as INR) is necessary if these medicines are used together.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Combining Levores with NSAIDs may increase the risk of central nervous system effects, including neuroexcitatory activities or convulsions.
  • Drugs that Prolong the QTc Interval: Co-administration with other medicines known to affect the heart’s electrical activity can increase the risk of QT interval prolongation and severe, irregular heart rhythms.
  • Oral Hypoglycemic Agents/Insulin: Concomitant use with drugs for diabetes can result in significant disturbances in blood glucose levels, including both severe hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar). Careful blood glucose monitoring is required.

Mechanism of Action

Dual Inhibition of DNA Gyrase and Topoisomerase IV

Levores' mechanism of action is focused on the direct, lethal interference with a bacterial cell's fundamental processes, leading to the bactericidal effect (killing of the pathogen) rather than bacteriostasis (growth suppression). This action is confined to two primary mechanistic domains that govern the maintenance and replication of the bacterial genome. The molecule acts as a DNA Topoisomerase Poison, binding to and inhibiting two critical bacterial enzymes: DNA Gyrase and Topoisomerase IV.

Driving the Bactericidal Cascade

This molecular interaction forms a stable, lethal complex with the enzyme and the DNA, trapping the DNA strands in a cleaved state. This cascade results in the rapid accumulation of catastrophic double-strand DNA breaks, which is a critical step in the resulting cellular breakdown. By simultaneously disrupting DNA replication and chromosome segregation pathways, Levores prevents the bacterial cell from successfully maintaining its genetic integrity. This irreversible cellular failure culminates in bacterial cell death and a concentration-dependent killing of the bacterial cell population.

Constraints on Mechanism Efficacy

The mechanism's effectiveness is constrained by mutations in the enzyme active sites (QRDR), which physically prevent the formation of the inhibitory complex. It is also limited by efflux pumps that actively transport the molecule out of the bacterial cytoplasm, reducing the drug's concentration below the required inhibitory threshold at the enzyme binding site.

Dosage and Administration Information

How to Use Levores (Levofloxacin): Administration Guidelines

Levores is administered via approved routes that include Oral (using tablets or solution), Intravenous (IV) infusion for systemic use, and Topical application for the ophthalmic solution. The oral and IV forms are generally considered interchangeable at the same mg/mg dose for systemic therapy.

Dosing and Frequency

Systemic use of Levores typically follows a once-daily (q24h) regimen for adults. Adult doses are 250 mg, 500 mg, or 750 mg, with the dose and treatment duration dictated by the specific therapeutic regimen. Treatment duration varies widely, ranging from short courses of 3 days for certain infections up to 60 days for conditions like Inhalational Anthrax post-exposure prophylaxis.

Administration Requirements

Oral Intake: Levores tablets may be taken with or without food. However, the oral solution is typically taken either one hour before or two hours after meals. To prevent reduced absorption, oral Levores is taken at least two hours before or two hours after taking products containing multivalent cations, such as iron supplements, antacids, or sucralfate.

IV Infusion: The intravenous solution is administered slowly. Doses of 250 mg and 500 mg require infusion over 60 minutes, while the 750 mg dose is infused over 90 minutes.

Population Adjustments

A dose adjustment is required for adult patients with reduced renal function (creatinine clearance < 50 mL/min) to prevent drug accumulation, which involves reducing the dose or extending the interval to every 48 hours. No specific dose adjustment is needed for patients with hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levores

The research for Levores (Levofloxacin) is primarily based on formal clinical trials and systematic reviews, which governmental health authorities rely on for evaluation. These studies focus on examining the patterns of outcomes in specific groups of patients under controlled conditions.

Evidence for Use in Systemic Respiratory and Urinary Tract Infections

The principal body of evidence for Levores in systemic infections comes from Randomized Controlled Trials (RCTs). Levores was studied for conditions such as Community-Acquired Pneumonia (CAP) and Complicated Urinary Tract Infections (cUTI) in adult populations. Research examined outcomes related to clinical response classifications and the measured rates of microbiologic eradication at specific follow-up visits.

Findings describe patterns observed in the studies where measurements related to clinical status were recorded. A key limitation is that many trials used an active comparator (another antibiotic) instead of a placebo, meaning studies were often designed to determine whether outcomes fell within the predefined range of results observed in the other established antibiotic regimens.

Evidence for Specialized, High-Risk Public Health Uses

For high-risk threats like Inhalational Anthrax and Plague, traditional human efficacy testing is not possible. Instead, the evidence is derived from the FDA Animal Rule, relying on Animal Efficacy Studies and Human Pharmacokinetic (PK) Studies.

The research examined observations in non-human primate models, where the primary measurement was related to the survival rate. In humans, research monitored the achievement of specific drug concentration levels in the plasma, which is used as a surrogate marker to indicate that the drug reaches the required levels. The primary uncertainty is that clinical performance is not measured directly in humans, and the evidence relies heavily on these surrogate markers and animal data.

Key Uncertainties and Research Gaps in the Evidence

Clinical trials typically use short- to intermediate-term follow-up periods (up to 28 days post-treatment). Therefore, there is limited information for long-term outcomes or durability of effect that extends significantly past the standard follow-up window. Additionally, data for patients with certain severe co-morbidities are often limited, as these subjects were sometimes excluded from the main efficacy trials.

Key Studies & References

  1. Levofloxacin Tablets/Injection Official Prescribing Information (DailyMed)
  2. Levofloxacin Injection, Solution (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Levores (FAQ)

Q: How quickly does Levores typically start working?

Levores is rapidly absorbed after being taken orally, with the highest concentration in the bloodstream typically reached within approximately 1 to 2 hours. This time relates to when the drug is most concentrated in the bloodstream.


Q: Do you have to take Levores forever, or can you stop?

Official documentation describes Levores as an antibiotic prescribed for short-term treatment courses only, which can range from a few days up to 60 days, depending on the condition being treated. It is not described in official documentation as a medication for long-term or chronic maintenance therapy.


Q: Is Levores the same as [Competitor Drug Name]?

Levores contains the active ingredient levofloxacin, which is chemically classified within the fluoroquinolone family of antibiotics. Official information notes that its effectiveness was often compared to other established antibiotic regimens in clinical studies to confirm its efficacy was comparable to other established antibiotic regimens.


Q: Can Levores cause confusion or memory issues?

Regulatory documents state that Levores has been associated with effects on the Central Nervous System (CNS). Specifically, adverse reactions reported in the official product information include both confusion and memory impairment.


Q: What is the difference between Levores and a placebo in clinical trials?

For most of its approved uses, Levores was studied by comparing it directly to another established antibiotic (an 'active comparator'), rather than an inactive placebo. This approach was common given the serious nature of the infections being treated. These studies primarily determined whether Levores produced comparable results to other standard regimens.


Q: What is the key research finding about Levores that supports its use?

Studies supporting the use of Levores demonstrated favorable measurements related to the killing of susceptible bacteria (microbiologic eradication) and clinical response classifications. This evidence is crucial for its approval in treating conditions like certain respiratory and urinary tract infections.


Q: How is Levores typically stopped, if necessary?

Levores is prescribed for a fixed duration of therapy, and regulatory information implies that the medication is generally stopped upon completion of the course. Official documentation does not typically specify a need for tapering the dose.


Q: Is it normal to feel tired when first starting Levores?

Official documentation notes that fatigue, or an unusual feeling of tiredness, was an adverse event observed in a small percentage of patients during clinical trials.


Q: How long does Levores stay in your system after taking a dose?

The time it takes for half of the drug to be cleared from the blood plasma is approximately 6 to 8 hours after a single dose. This is known as the average plasma elimination half-life for Levores.


Q: Is Levores a controlled substance or addictive?

Levores is classified as a fluoroquinolone antibiotic used to treat bacterial infections. According to major regulatory agencies, it is not scheduled or categorized as a controlled substance.


Q: Can Levores affect fertility or reproductive health?

Regulatory documents indicate there are no complete human studies that have evaluated the effects of Levores on fertility. However, non-clinical toxicology studies performed in animals did not show evidence of impaired fertility.


Q: Can Levores be split in half if the pill is too large?

Official product information for Levores tablets does not generally state that the tablets are scored (marked to be split). Unless a tablet is explicitly designed and marked to be divided, official labeling advises that tablets should generally be taken whole.


Q: Why do doctors prescribe Levores instead of other options?

Levores is approved for treating specific infections, particularly when a doctor determines a patient needs an antibiotic with a particular spectrum of activity. It may be prescribed when other first-line treatments are not appropriate or when a specific pathogen is known to be susceptible to this drug.


Q: Does Levores have a generic version available?

Yes, Levores is available as the generic medicine levofloxacin. The generic version has been approved by the FDA for use in both oral tablets and injectable solutions.


Q: Are there any specific supplements or vitamins that interact with Levores?

Official labeling specifies that Levores should not be taken within two hours of products containing multivalent cations, which includes supplements containing minerals like iron or zinc. Taking them too closely can significantly reduce the amount of the drug the body absorbs.


Q: How does taking Levores impact driving ability?

Levores is associated with Central Nervous System (CNS) side effects such as dizziness, lightheadedness, and other nervous system symptoms. Official warnings note that these effects could potentially impair a person's judgment, thinking, or motor skills.


Q: What is the risk of overdose associated with Levores?

In the event of an acute overdose, the most common effects reported include Central Nervous System symptoms such as confusion, tremor, or convulsions. Cardiac effects, such as a lengthening of the QT interval (a heart rhythm measurement), are also expected.


Q: Do men and women experience different side effects from Levores?

The regulatory safety sections generally group adverse events across the entire patient population. However, some differences were observed in clinical trial data, such as the reporting of vaginitis was noted in a small percentage of patients.


Q: Can Levores cause dry mouth?

Yes, official documentation lists dry mouth as an adverse event. It was observed in clinical trials at a rate of less than 1.0% of patients.


Q: Is a rash a serious side effect of Levores?

While a minor rash can occur, official warnings emphasize that a skin rash, or blistering, should be monitored closely. This is because it may be the first sign of a potentially life-threatening hypersensitivity reaction, such as Stevens-Johnson syndrome.


Q: Are there long-term studies on the effects of Levores on the heart?

Official safety warnings note two main risks to the heart. The drug is known to prolong the QT interval, a measure of the heart's electrical cycle. Furthermore, the fluoroquinolone class is associated with a rare but serious risk of aortic aneurysm or dissection.


Q: Are there any known interactions between Levores and birth control pills?

Some antibiotics, including those in the fluoroquinolone class, have the potential to reduce the effectiveness of oral contraceptives that contain hormones. Additionally, the iron content found in the inactive (placebo) birth control pills can potentially interfere with Levores absorption.

How should Levores be stored and disposed of?

Storage Requirements for Levores

Levores (levofloxacin) must be stored at Controlled Room Temperature, typically maintained between 20 C and 25 C. Official labeling requires the medication to be protected from light and it must not be frozen to maintain product stability.

Tablets and oral solutions should be kept in the original, tightly closed container and stored out of the sight and reach of children to prevent accidental exposure.

Stability and Disposal

Adherence to stability limits is mandatory: any unused portion of a single-use injectable container must be discarded immediately after administration. The oral solution must be discarded 60 days after first opening.

Disposal of unused or expired Levores should be conducted through an authorized medicine take-back program or specific household trash preparation, as the medication must not be flushed down the toilet or poured down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levores found in:

A-Z Index: